Gilead Sciences, Inc. with ticker code (GILD) have now 26 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between $123.00 and $68.50 calculating the mean target price we have $82.49. Given that the stocks previous close was at $84.17 this is indicating there is a potential downside of -2.0%. The day 50 moving average is $78.86 and the 200 moving average now moves to $73.75. The market cap for the company is 105.31B. The stock price is currently at: $84.59 USD
The potential market cap would be $103,205,576,271 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 103.15, revenue per share of $22.30 and a 11.55% return on assets.
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.
